Table 2 Treatment characteristics and overall survival in patients with metastatic disease
From: Breast cancer in moroccan young women: a retrospective study
| Â | No. of patients(%) | 3-Year OS(%) | Median OS | p | |
|---|---|---|---|---|---|
| Â | Â | Â | Months | 95%CI | Â |
Surgery | |||||
Yes | 18(34) | - | - | - | - |
No | 35 (66) | - | - | - | Â |
Metastatic First line Chemotherapy | |||||
No chemotherapy | 6(11.3) | 50 | 20.2 | 0 - 40.4 | 0.40 |
Chemotherapy | 47(88.7) | 57.7 | 39 | 30.6 - 47.3 | Â |
Chemotherapy protocol | |||||
AC 60 | 37(78.7) | 57.7 | 41.4 | 21.6 - 61.2 | 0.65 |
FEC 100 | 6(12.8) | 33.3 | 35.1 | 30.4 - 39.8 | Â |
AT | 4(8.5) | NR | 39 | NR | Â |
Hormonotherapy | |||||
No hormonotherapy | 41(77.4) | 58.3 | 39 | 27.1 -50.8 | 0.60 |
hormonotherapy | 12(22.6) | 48.4 | 35.1 | 5.5 - 64.8 | Â |